Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
Source: STAT News
STAT+: Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
You may also like
Insurers Hedge on Trump-Backed Pledge To Improve...
Violence Repeatedly Erupts at Dementia Care Facilities...
Doctors ‘Cringe’ at Possibility of Documenting...
Pregnant Woman’s Roadside Death Triggers Push To...
Tempus to buy cancer test-maker Personalis for $1.5B
Resmed ventilator safety issue linked to 5 serious...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.